Opportunities in the Sickle Cell Disease market include advancing gene-editing therapies like EDIT-301, expanding VOC-reducing treatments such as inclacumab, and exploring novel drug candidates like ...

Recent therapies like hydroxyurea (Droxia, Bristol-Myers Squibb), the first FDA-approved drug for SCD in 1994, increase fetal ...

This article is part of “Innovations In: Sickle Cell Disease,” an editorially independent special report that was produced with financial support from Vertex Pharmaceuticals. Sickle cell disease was ...

Sickle Cell Disease is a chronic, inherited blood disorder that affects millions of people worldwide. It is best known for causing anaemia, pain episodes, and organ complications, but a lesser-known ...

Given the remarkable advances seen with gene therapies for sickle cell disease (SCD), it may seem counterintuitive to suggest the space may be in need of more therapies that have already been ...

Sickle cell anemia (HbSS) is the homozygous dominant variant and the most common and severe form of the disease. Whereas ...

OMAHA, Neb. (WOWT) - Nobel Prize-winning technology offers a potential cure for sickle cell disease. Simply put, doctors can edit a patient’s genes to alter blood cells. But this gene editing ...

Because SCD can impair blood and oxygen delivery to any part of the body, it can cause a wide range of complications, including anemia, blood clots, and stroke. It can also damage organs, such as the ...

DURHAM, N.C. (WTVD) -- Blood donations are needed now more than ever, but there's a call for a diverse blood supply, according to the Red Cross. As Black History Month is commemorated, the ...

On Saturday, the American Red Cross hosted a blood drive in Hartford to commemorate Sickle Cell Awareness Month. The Red Cross also plans to host a blood drive at Total Mortgage Arena in Bridgeport on ...